Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia

Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia

The purpose of this study is to assess real-world effectiveness and safety of oral azacitidine in adults diagnosed with acute myeloid leukemia (AML) in Hong Kong

Inclusion Criteria:

• Documented diagnosis of Acute Myeloid Leukemia (AML).
• Achieved first complete response (CR) or complete response with incomplete blood recovery (CRi) following intensive induction chemotherapy.
• Not able or unwilling to undergo Hematopoietic Stem Cell Transplantation (HSCT).
• Received oral azacitidine as maintenance therapy after first CR or CRi following intensive induction chemotherapy in real-world settings (Note: CR/CRi status at oral azacitidine treatment initiation is left to the judgment of the local clinicians depending on the treatment response and the condition of the patient in routine clinical practices).
• Age ≥ 18 years at the index date (oral azacitidine initiation date).

Exclusion Criteria:

• Evidence of relapse prior to oral azacitidine initiation recorded in electronic health record (EHR).